Sands Capital Management LLC Takes $12.26 Million Position in argenex SE $ARGX

Sands Capital Management LLC bought a new position in shares of argenex SE (NASDAQ:ARGX) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 16,625 shares of the company’s stock, valued at approximately $12,262,000.

Several other institutional investors have also recently added to or reduced their stakes in ARGX. Ameriflex Group Inc. acquired a new stake in argenex during the 3rd quarter worth approximately $32,000. Bessemer Group Inc. lifted its holdings in shares of argenex by 276.5% during the third quarter. Bessemer Group Inc. now owns 64 shares of the company’s stock worth $47,000 after purchasing an additional 47 shares during the period. MAI Capital Management grew its position in argenex by 866.7% in the 2nd quarter. MAI Capital Management now owns 87 shares of the company’s stock valued at $48,000 after buying an additional 78 shares during the last quarter. Mather Group LLC. acquired a new position in argenex in the 3rd quarter valued at $50,000. Finally, Rossby Financial LCC raised its position in argenex by 115.2% during the 3rd quarter. Rossby Financial LCC now owns 71 shares of the company’s stock worth $54,000 after buying an additional 38 shares during the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenex Stock Performance

ARGX opened at $742.79 on Wednesday. The company has a market cap of $45.96 billion, a price-to-earnings ratio of 38.05, a PEG ratio of 1.22 and a beta of 0.38. argenex SE has a one year low of $510.05 and a one year high of $934.62. The business’s fifty day moving average is $811.69 and its two-hundred day moving average is $817.18.

argenex (NASDAQ:ARGX) last released its quarterly earnings results on Thursday, February 26th. The company reported $8.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.05 by $1.97. argenex had a return on equity of 38.51% and a net margin of 30.42%.The business had revenue of $1.32 billion during the quarter, compared to the consensus estimate of $1.30 billion. On average, analysts predict that argenex SE will post 3.13 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ARGX. DZ Bank upgraded shares of argenex to a “strong-buy” rating in a research note on Friday, December 19th. Wall Street Zen downgraded argenex from a “buy” rating to a “hold” rating in a research note on Sunday. Morgan Stanley raised their price target on argenex from $1,070.00 to $1,110.00 and gave the company an “overweight” rating in a report on Thursday, December 4th. Stifel Nicolaus upped their price objective on argenex from $1,028.00 to $1,248.00 and gave the stock a “buy” rating in a report on Thursday, December 11th. Finally, Wedbush reissued an “outperform” rating and issued a $1,000.00 target price on shares of argenex in a report on Monday. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, argenex presently has a consensus rating of “Moderate Buy” and an average price target of $999.22.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.